TY - JOUR
T1 - Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer
AU - Ingle, James N.
AU - Come, Steven
AU - Ellis, Matthew
AU - Santen, Richard
AU - Bissell, Mina
AU - Schiff, Rachel
AU - Goss, Paul
PY - 2004/1/28
Y1 - 2004/1/28
N2 - The introduction of the nonsteroidal aromatase inhibitor (NS-AI) anastrozole as an alternative to tamoxifen for adjuvant therapy of women with resected hormone receptor-positive breast cancer has added a management category into which patients presenting with metastatic disease can be placed. There are now essentially three such categories: (a) tamoxifen sensitive (no prior AI); (b) tamoxifen resistant (no prior AI); and (c) NS-AI resistant (no prior tamoxifen). Well-conducted Phase III trials provide evidence for choosing first-line therapy for advanced disease in categories a and b. In tamoxifen-sensitive patients, one can choose either NS-AI, anastrozole, or letrozole. In tamoxifen-resistant patients, one can choose either of the NS-AIs, the steroidal AI exemestane, or the estrogen receptor down-regulator fulvestrant. The situation is quite different for patients in category c. There are no Phase III trials of agents in patients who have experienced disease progression on a NS-AI. Phase II data are available for exemestane and high-dose estrogens, and retrospective data are available for tamoxifen and fulvestrant. Additional clinical trials are needed to determine an optimal sequencing strategy.
AB - The introduction of the nonsteroidal aromatase inhibitor (NS-AI) anastrozole as an alternative to tamoxifen for adjuvant therapy of women with resected hormone receptor-positive breast cancer has added a management category into which patients presenting with metastatic disease can be placed. There are now essentially three such categories: (a) tamoxifen sensitive (no prior AI); (b) tamoxifen resistant (no prior AI); and (c) NS-AI resistant (no prior tamoxifen). Well-conducted Phase III trials provide evidence for choosing first-line therapy for advanced disease in categories a and b. In tamoxifen-sensitive patients, one can choose either NS-AI, anastrozole, or letrozole. In tamoxifen-resistant patients, one can choose either of the NS-AIs, the steroidal AI exemestane, or the estrogen receptor down-regulator fulvestrant. The situation is quite different for patients in category c. There are no Phase III trials of agents in patients who have experienced disease progression on a NS-AI. Phase II data are available for exemestane and high-dose estrogens, and retrospective data are available for tamoxifen and fulvestrant. Additional clinical trials are needed to determine an optimal sequencing strategy.
UR - http://www.scopus.com/inward/record.url?scp=1642568637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642568637&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-031200
DO - 10.1158/1078-0432.CCR-031200
M3 - Article
C2 - 14734492
AN - SCOPUS:1642568637
SN - 1078-0432
VL - 10
SP - 362s-367s
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1 II
ER -